• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Atrion Corporation

    8/21/24 9:14:49 AM ET
    $ATRI
    Medical/Dental Instruments
    Health Care
    Get the next $ATRI alert in real time by email
    SC 13D/A 1 d874802dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    ATRION CORPORATION

    (Name of Issuer)

    COMMON STOCK, $0.10 PAR VALUE PER SHARE

    (Title of Class of Securities)

    049904105

    (CUSIP Number)

    Jennifer McDonough

    Executive Vice President,

    General Counsel and Secretary

    Nordson Corporation

    28601 Clemens Road

    Westlake, Ohio 44145

    (440) 892-1580

    with a copy to:

    James Dougherty

    Shanu Bajaj

    Davis Polk & Wardwell LLP

    450 Lexington Avenue

    New York, NY 10017

    (212) 450-4000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    August 21, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format will include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page will be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page will not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but will be subject to all other provisions of the Act (however, see the Notes).

     

     

     


     (1)    

     Names of reporting persons

     

     Nordson Corporation

     (2)  

     Check the appropriate box if a member of a group (see instructions)

     (a) ☐  (b) ☒

     

     (3)  

     SEC use only

     

     (4)  

     Source of funds (see instructions)

     

     OO

     (5)  

     Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     ☐

     (6)  

     Citizenship or place of organization

     

     Ohio

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with

     

        (7)     

     Sole voting power

     

     0

        (8)   

     Shared voting power

     

     0

        (9)   

     Sole dispositive power

     

     0

       (10)   

     Shared dispositive power

     

     0

    (11)    

     Aggregate amount beneficially owned by each reporting person

     

     0

    (12)  

     Check box if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

     ☐

    (13)  

     Percent of class represented by amount in Row (11)

     

     0%

    (14)  

     Type of reporting person (see instructions)

     

     CO


    Explanatory Note

    Introduction

    This Amendment No. 1 to Schedule 13D (this “Amendment”) amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission on May 30, 2024 (the “Original Schedule 13D”) and is being filed by the undersigned, pursuant to §240.13d-1(a), with respect to the common stock, par value $0.10 per share (“Common Stock”) of Atrion Corporation, a Delaware corporation (the “Issuer”). The principal executive offices of the Issuer are located at One Allentown Parkway, Allen, TX 75002. Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to them in the Original Schedule 13D.

    This Amendment constitutes an exit filing of Nordson Corporation (“Nordson” or the “Reporting Person”) in respect of the Common Stock previously reported as beneficially owned by the Reporting Person.

    Item 2. Identity and Background

    Item 2 is hereby amended and supplemented by adding the following information:

    As a result of the Merger, the Issuer is a wholly owned subsidiary of Nordson.

    Item 4. Purpose of Transaction

    Item 4 is hereby amended and supplemented by adding the following to the end thereof:

    On August 21, 2024, the transactions contemplated by the Merger Agreement were consummated, including the Merger, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Nordson. Pursuant to the terms of the Merger Agreement, each issued and outstanding share of Common Stock (other than shares of Common Stock (i) held in the treasury of the Issuer or owned by any direct or indirect wholly owned subsidiary of the Issuer immediately prior to the Effective Time, (ii) owned by Merger Sub, Nordson or any direct or indirect wholly owned subsidiary of Nordson immediately prior to the Effective Time, or (iii) held by a holder or beneficial holder that or who was entitled to demand and has properly demanded appraisal for such shares of Common Stock in accordance with, and that or who complied in all respects with, Section 262 of the General Corporation Law of the State of Delaware) was canceled and converted into the right to receive an amount in cash equal to $460.00 per share of Common Stock, without interest.

    At the Effective Time, the Voting Agreements and the associated proxies granted thereunder automatically terminated in accordance with the terms of the Voting Agreements.

    On August 21, 2024, in connection with the Merger, the Issuer notified The Nasdaq Global Select Market (“Nasdaq”) of the consummation of the Merger and requested that trading of the shares of Common Stock on Nasdaq be suspended prior to the opening of trading on August 21, 2024. In addition, at the Issuer’s request, Nasdaq filed with the SEC an application on Form 25 to delist the shares of Common Stock from Nasdaq and deregister the shares of Common Stock under Section 12(b) of the Securities and Exchange Act of 1934, as amended (the “Act”). Trading of shares of Common Stock on Nasdaq was suspended prior to the opening of trading on August 21, 2024. The Issuer intends to file with the SEC a Form 15 requesting that the Issuer’s reporting obligations under Section 13 and Section 15(d) of the Act be suspended.

    As a result of the foregoing and as of the Effective Time, to the extent the terms of the Voting Agreements may have resulted in the Reporting Person being deemed for purposes of Rule 13d-3 under the Exchange Act to beneficially own shares of Common Stock, the Reporting Person will no longer be deemed for purposes of Rule 13d-3 under the Exchange Act to beneficially own such shares of Common Stock.


    Item 5. Interest in Securities of the Issuer

    Item 5 is hereby amended and restated in its entirety as follows:

    (a)-(b) To the extent the terms of the Voting Agreements may have resulted in the Reporting Person being deemed for purposes of Rule 13d-3 under the Exchange Act to beneficially own shares of Common Stock, the Reporting Person will, as a result of the consummation of the Merger and the termination of the Voting Agreements, no longer be deemed for purposes of Rule 13d-3 under the Exchange Act to beneficially own such shares of Common Stock, and the filing of this Amendment represents the final amendment to the Original Schedule 13D and constitutes an “exit” filing for the Reporting Person.

    (c) Except as set forth in this Amendment with reference to the Merger Agreement and the Voting Agreements and the transactions contemplated by those agreements, and except as previously reported by the Issuer, the Reporting Person or any of the persons set forth on Annex A to the Original Schedule 13D, neither the Reporting Person nor, to the Reporting Person’s knowledge, any of the persons listed on Annex A to the Original Schedule 13D, has effected any transaction in the shares of Common Stock during the past 60 days.

    (d) Except with reference to the Merger Agreement and the Voting Agreements and the transactions contemplated by those agreements, and except as set forth in this Amendment and the Original Schedule 13D, neither the Reporting Person nor, to the knowledge of the Reporting Person, any of the persons set forth on Annex A to the Original Schedule 13D has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities of the Issuer previously reported on the Original Schedule 13D.

    (e) As of August 21, 2024 and as a result of the consummation of the Merger and the termination of the Voting Agreements (and associated proxies granted thereunder), to the extent the terms of the Voting Agreements may have resulted in the Reporting Person being deemed for purposes of Rule 13d-3 under the Exchange Act to beneficially own shares of Common Stock, the Reporting Person ceased to beneficially own more than five percent of Common Stock. Consequently, this Amendment constitutes an exit filing for the Reporting Persons.

    Item 6. Interest in Securities of the Issuer

    Item 6 of the Original 13D is hereby amended and supplemented by adding the following at the end thereof:

    The information set forth in Item 4 of this Amendment is incorporated by reference herein.

    Item 7. Material to be Filed as Exhibits

     

    Exhibit

    No.

       Description
    1    Agreement and Plan of Merger, dated as of May 28, 2024, by and among Nordson Corporation, Alpha Medical Merger Sub, Inc., and Atrion Corporation (filed as Exhibit 2.1 to Nordson’s Current Report on Form 8-K filed with the SEC on August 21, 2024 and incorporated herein by reference).
    2    Voting and Support Agreement, dated as of May 28, 2024, by and among Nordson Corporation, Montclair Harbour LLC, David A. Battat and Emile A. Battat (filed as Exhibit 2.2 to Nordson’s Current Report on Form 8-K filed with the SEC on May 29, 2024 and incorporated herein by reference).
    3    Voting and Support Agreement, dated as of May 28, 2024, by and among Nordson Corporation, Stupp Bros., Inc. and John P. Stupp Jr. (filed as Exhibit 2.3 to Nordson’s Current Report on Form 8-K filed with the SEC on May 29, 2024 and incorporated herein by reference).
    4    Form of Voting and Support Agreement (filed as Exhibit 4 to Nordson’s Original Schedule 13D filed with the SEC on May 30, 2024 and incorporated herein by reference).


    SIGNATURES

    After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: August 21, 2024

     

    NORDSON CORPORATION
    By:   /s/ Jennifer McDonough
     

    Name:  Jennifer McDonough

     

    Title:   Executive Vice President, General Counsel and Secretary

    Get the next $ATRI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ATRI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Stupp John P Jr returned $69,149,960 worth of shares to the company (150,326 units at $460.00), closing all direct ownership in the company (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      8/21/24 5:00:44 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Director Spaulding Ronald Nicholas returned $1,231,880 worth of shares to the company (2,678 units at $460.00), closing all direct ownership in the company (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      8/21/24 4:30:30 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Director Athey Preston G returned $629,280 worth of shares to the company (1,368 units at $460.00), closing all direct ownership in the company (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      8/21/24 4:19:38 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ATRI
    SEC Filings

    See more

    $ATRI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Atrion Reports Second Quarter 2024 Results

      ALLEN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the second quarter ended June 30, 2024. Revenues for the second quarter of 2024 totaled $48.8 million compared to $43.8 million for the same period in 2023. For the just ended quarter, operating income was $0.5 million, down $6.8 million from the comparable 2023 period, and net income was $0.4 million, down $6.2 million from the same period in 2023. Operating income was significantly impacted by the accrual of $5.0 million in acquisition-related expenses discussed below. Second quarter 2024 diluted earnings per share were $0.23 compared to $3.73 for the second quarter of 20

      8/8/24 6:00:00 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Atrion Corporation Enters Into Merger Agreement with Nordson Corporation

      ALLEN, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million. The transaction enterprise value reflects a multiple of 20.2 times Atrion's 2023 EBITDA, and the $460 per share price represents a 15% premium to Atrion's 90-day average daily volume-weighted average stock price. The proposed transaction was unanimously approved by the Boards of Directors of Atrion

      5/28/24 7:24:38 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Nordson Corporation Announces Agreement to Acquire Atrion Corporation, a Market Leader in Medical Infusion and Cardiovascular Technologies

      Expands Nordson MEDICAL's total addressable market Highly complementary with Nordson's customer base and core competencies Broadens Nordson's exposure to higher-growth and stable medical end markets Nordson to host investor call at 8:30 a.m. ET today Nordson Corporation (NASDAQ:NDSN) today announced that it has entered into a definitive agreement to acquire Atrion Corporation (NASDAQ:ATRI), a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions, for $460.00 per share in cash. This reflects a valuation of 15X Atrion's 2024 full-year estimated EBITDA, inclusive of synergies Nordson expects to generate in the first two years of its ownership. Th

      5/28/24 7:00:00 AM ET
      $ATRI
      $NDSN
      Medical/Dental Instruments
      Health Care
      Industrial Machinery/Components
      Industrials
    • SEC Form 15-12G filed by Atrion Corporation

      15-12G - ATRION CORP (0000701288) (Filer)

      9/3/24 9:11:57 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Atrion Corporation

      S-8 POS - ATRION CORP (0000701288) (Filer)

      8/21/24 9:24:19 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Atrion Corporation

      S-8 POS - ATRION CORP (0000701288) (Filer)

      8/21/24 9:23:12 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Athey Preston G bought $95,904 worth of shares (300 units at $319.68), increasing direct ownership by 28% to 1,368 units (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      12/1/23 2:53:55 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Battat David A bought $90,000 worth of shares (300 units at $300.00), increasing direct ownership by 0.77% to 39,400 units (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      11/16/23 2:49:33 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    Financials

    Live finance-specific insights

    See more
    • Atrion Reports Second Quarter 2024 Results

      ALLEN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the second quarter ended June 30, 2024. Revenues for the second quarter of 2024 totaled $48.8 million compared to $43.8 million for the same period in 2023. For the just ended quarter, operating income was $0.5 million, down $6.8 million from the comparable 2023 period, and net income was $0.4 million, down $6.2 million from the same period in 2023. Operating income was significantly impacted by the accrual of $5.0 million in acquisition-related expenses discussed below. Second quarter 2024 diluted earnings per share were $0.23 compared to $3.73 for the second quarter of 20

      8/8/24 6:00:00 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Nordson Corporation Announces Agreement to Acquire Atrion Corporation, a Market Leader in Medical Infusion and Cardiovascular Technologies

      Expands Nordson MEDICAL's total addressable market Highly complementary with Nordson's customer base and core competencies Broadens Nordson's exposure to higher-growth and stable medical end markets Nordson to host investor call at 8:30 a.m. ET today Nordson Corporation (NASDAQ:NDSN) today announced that it has entered into a definitive agreement to acquire Atrion Corporation (NASDAQ:ATRI), a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions, for $460.00 per share in cash. This reflects a valuation of 15X Atrion's 2024 full-year estimated EBITDA, inclusive of synergies Nordson expects to generate in the first two years of its ownership. Th

      5/28/24 7:00:00 AM ET
      $ATRI
      $NDSN
      Medical/Dental Instruments
      Health Care
      Industrial Machinery/Components
      Industrials
    • Atrion Corporation Declares Quarterly Cash Dividend

      ALLEN, Texas, May 21, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced that its Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock. This dividend will be payable on June 28, 2024 to stockholders of record at the close of business on June 14, 2024. Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com. Contact: Cindy FergusonVice President and Chief Financial Officer(972) 390-9800         

      5/21/24 4:30:00 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Atrion Corporation

      SC 13G/A - ATRION CORP (0000701288) (Subject)

      9/9/24 4:05:03 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Atrion Corporation

      SC 13D/A - ATRION CORP (0000701288) (Subject)

      8/22/24 6:05:08 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Atrion Corporation

      SC 13D/A - ATRION CORP (0000701288) (Subject)

      8/22/24 6:04:56 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care